• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Wave Life Sciences Ltd.

    11/12/24 8:09:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email
    S-8 1 d842749ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on November 12, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    WAVE LIFE SCIENCES LTD.

    (Exact name of registrant as specified in its charter)

     

     

     

    Singapore   98-1356880

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

    7 Straits View #12-00, Marina One East Tower

    Singapore

      018936
    (Address of Principal Executive Offices)   (Zip Code)

    Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended

    (Full title of the plan)

    CT Corporation

    155 Federal Street, Suite 700

    Boston, MA 02110

    (617) 757-6400

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    William C. Hicks, Esq.

    John T. Rudy, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    One Financial Center

    Boston, MA 02111

    (617) 542-6000

     

    Linda Rockett, Esq.

    Senior Vice President, General Counsel

    Wave Life Sciences Ltd.

    c/o 733 Concord Avenue

    Cambridge, MA 02138

    (617) 949-2900

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This registration statement registers an aggregate of 5,000,000 additional ordinary shares of Wave Life Sciences Ltd. (the “Registrant”) reserved under the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended (the “2021 Plan”), representing an increase of 5,000,000 ordinary shares reserved under the 2021 Plan effective August 6, 2024. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (File No. 333-259196) relating to an employee benefit plan is effective. The information contained in the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on August 31, 2021 (File No.  333-259196) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 6, 2024 (File No. 001-37627) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Amendment No.  1 to the Annual Report on Form 10-K/A filed on April 29, 2024 (File No.  001-37627) under the Exchange Act.

    (b) The portions of the Registrant’s definitive proxy statement on Schedule 14A filed on June 21, 2024 (File No. 001-37627) that are deemed “filed” with the Commission under the Exchange Act.

    (c) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 filed on May 10, 2024 (File No. 001-37627) under the Exchange Act, the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed on August 8, 2024 (File No. 001-37627) under the Exchange Act, and the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 filed on November 12, 2024 (File No. 001-37627) under the Exchange Act.

    (d) The Registrant’s Current Reports on Form 8-K filed on January  4, 2024, June  25, 2024, August  12, 2024, September  24, 2024, September  26, 2024, October  15, 2024, October  16, 2024, and October 30, 2024 (File No. 001-37627) under the Exchange Act (in each case, except for information contained therein which is furnished rather than filed).

    (e) The description of the Registrant’s Ordinary Shares contained in the Registrant’s Registration Statement on Form 8-A filed on November 9, 2015 (File No. 001-37627) under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    (f) All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 8. EXHIBITS.

     

    Exhibit Number

      

    Description

      4.1*

       Constitution (formerly known as Memorandum of Association and Articles of Association).

      4.2**

       Form of Specimen Ordinary Share Certificate.

      4.3.1***

       Investors’ Rights Agreement by and among the Registrant and certain of its shareholders, dated as of August 14, 2015.

      4.3.2****

       Amendment No.  1 to Investors’ Rights Agreement by and among the Registrant and certain of its shareholders, dated as of November 8, 2018.


      4.4*****

       Share Purchase Agreement by and between the Registrant and C.P. Pharmaceuticals International C.V., dated as of May 5, 2016.

      4.5******

       Investor Agreement by and among the Registrant and Takeda Pharmaceutical Company Limited, dated as of April 2, 2018.

      4.6*******

       Share Purchase Agreement by and between the Registrant and Takeda Pharmaceutical Company Limited, dated as of February 19, 2018.

      4.7********

       Investor Agreement by and between the Registrant and Glaxo Group Limited, dated as of January 26, 2023.

      4.8*********

       Share Purchase Agreement by and between the Registrant and Glaxo Group Limited, dated as of December 13, 2022.

      4.9**********

       Form of Pre-Funded Warrant (2022).

      4.10***********

       Form of Pre-Funded Warrant (2024).

      5.1

       Opinion of WongPartnership LLP.

     23.1

       Consent of KPMG LLP, independent registered public accounting firm.

     23.2

       Consent of WongPartnership LLP (included in Exhibit 5.1).

     24.1

       Powers of Attorney (included on the signature page to this Registration Statement).

     99.1@+

       Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended.

     99.2@++

       Form of Non-qualified Share Option Agreement under the 2021 Equity Incentive Plan, as amended, effective as August 10, 2021.

     99.3@+++

       Form of Restricted Share Unit Agreement under the 2021 Equity Incentive Plan, as amended, effective as of August 10, 2021.

     99.4@++++

       Form of Non-qualified Share Option Agreement for UK Participants under the 2021 Equity Incentive Plan, as amended, effective as of August 10, 2021.

     99.5@+++++

       Form of Restricted Share Unit Agreement for UK Participants under the 2021 Equity Incentive Plan, as amended, effective as of August  10, 2021.

    107

       Filing Fee Table.

     

    *

    Previously filed as Exhibit 3.2 to Amendment No. 5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on November 10, 2015 and incorporated herein by reference.

    **

    Previously filed as Exhibit 4.1 to Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on November 6, 2015 and incorporated herein by reference.

    ***

    Previously filed as Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on October 9, 2015 and incorporated herein by reference.

    ****

    Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 9, 2018 and incorporated herein by reference.

    *****

    Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on August 15, 2016 and incorporated herein by reference. Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Commission.

    ******

    Previously filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on May 9, 2018 and incorporated herein by reference.

    *******

    Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on May 9, 2018 and incorporated herein by reference.

    ********

    Previously filed as Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-37627), filed with the Commission on March 23, 2023 and incorporated herein by reference.


    *********

    Previously filed as Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-37627), filed with the Commission on March 23, 2023 and incorporated herein by reference.

    **********

    Previously filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on June 14, 2022 and incorporated herein by reference.

    ***********

    Previously filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on September 26, 2024 and incorporated herein by reference.

    +

    Previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on August 12, 2024 and incorporated herein by reference.

    ++

    Previously filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference.

    +++

    Previously filed as Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference.

    ++++

    Previously filed as Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference.

    +++++

    Previously filed as Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference.

    @

    Management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on November 12, 2024.

     

    Wave Life Sciences Ltd.
    By:   /s/ Paul B. Bolno, M.D., MBA
      Paul B. Bolno, M.D., MBA
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul B. Bolno, M.D., MBA and Kyle Moran, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Paul B. Bolno, M.D., MBA

    Paul B. Bolno, M.D., MBA

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      November 12, 2024

    /s/ Kyle Moran

    Kyle Moran

      

    Chief Financial Officer

    (Principal Financial Officer and

    Principal Accounting Officer)

      November 12, 2024

    /s/ Christian Henry

    Christian Henry

       Chairman of the Board   November 12, 2024

    /s/ Mark H. N. Corrigan, M.D.

    Mark H. N. Corrigan, M.D.

       Director   November 12, 2024

    /s/ Peter Kolchinsky, Ph.D.

    Peter Kolchinsky, Ph.D.

       Director   November 12, 2024

    /s/ Adrian Rawcliffe

    Adrian Rawcliffe

       Director   November 12, 2024

    /s/ Ken Takanashi, MBA, CPA

    Ken Takanashi, MBA, CPA

       Director   November 12, 2024

    /s/ Aik Na Tan

    Aik Na Tan

       Director   November 12, 2024

    /s/ Gregory L. Verdine, Ph.D.

    Gregory L. Verdine, Ph.D.

       Director   November 12, 2024

    /s/ Heidi L. Wagner, J.D.

    Heidi L. Wagner, J.D.

       Director   November 12, 2024
    Get the next $WVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    2/5/2026$38.00Buy
    BofA Securities
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    10/20/2025$18.00Overweight
    Wells Fargo
    8/4/2025$19.00Buy
    Canaccord Genuity
    7/28/2025$24.00Outperform
    Oppenheimer
    7/16/2025$16.00Buy
    Citigroup
    6/11/2025$14.00Outperform
    Raymond James
    More analyst ratings

    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    10/1/24 5:54:39 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Francis Chris exercised 9,375 units of Ordinary Shares at a strike of $3.14 and sold $150,260 worth of Ordinary Shares (9,375 units at $16.03) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    1/6/26 9:30:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Francis Chris exercised 441,031 units of Ordinary Shares at a strike of $4.78 and sold $6,427,085 worth of Ordinary Shares (441,031 units at $14.57) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/10/25 9:45:07 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Wave Life Sciences Ltd.

    SCHEDULE 13G - Wave Life Sciences Ltd. (0001631574) (Subject)

    2/5/26 1:40:12 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Wave Life Sciences Ltd.

    8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    2/2/26 7:41:34 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition

    8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    1/12/26 7:35:22 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

    WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 Data from the 400 mg multidose cohort of RestorAATion-2 clinical trial remain on track for first quarter of 2026 and data from the 600 mg single and multidose cohorts are expected in 2026 Research collaboration with GSK is ongoing and continues to expand with fourth program now selected to advance Wa

    2/2/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

    Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026 Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat loss similar to GLP-1 at three months with muscle preservation and the potential for once or twice-yearly dosing; higher dose and longer follow-up data from INLIGHT anticipated in 2026, including three-month 400 mg and six-month 240 mg data on track for this quarter Extending leadership in RNA editing following first-ever

    1/12/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. A live webcast of the presentation can be accessed by visiting "Investor Events" on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be arch

    1/5/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Wave Life Sciences with a new price target

    Wedbush reiterated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $33.00 from $20.00 previously

    12/12/25 8:29:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Wave Life Sciences from Sector Perform to Outperform and set a new price target of $27.00

    12/9/25 8:38:23 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Leadership Updates

    Live Leadership Updates

    View All

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

    5/9/24 7:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

    BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

    3/21/22 7:05:00 AM ET
    $ATHA
    $WVE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

    SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    10/1/24 5:47:15 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

    Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measur

    12/8/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

    CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave's proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. A webcast of the conference call can be accessed by visiting "Investor Events" on the investor relations sec

    12/7/25 4:00:00 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

    WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models  Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to recapitulate the MZ phenotype with WVE-006, GalNAc-RNA editing oligonucleotide, in RestorAATion-2 trial: AAT protein exceeded 20 µM during an acute phase response, basal AAT levels reached 13 µM, wi

    11/10/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care